[Clinical study on ceftazidime in the field of pediatrics].

Ceftazidime (CAZ), developed by Glaxo U.K., was used in pediatric patients with acute infections, and the following results were obtained. The mean blood concentrations of CAZ in 2 children were 142, 70.3, 46.9, 35.7, 16.2, 5.82 and 2.36 micrograms/ml at 5, 15, 30 minutes, 1, 2, 4 and 6 hours, respectively, after start of 5 minutes' intravenous injection of 20 mg/kg, with the half-life of 1.25 hours. CAZ was administered to 19 pediatric patients with acute infections. Out of them, 15 patients, i.e., 3 with acute tonsillitis, 1 with acute bronchitis, 5 with bronchopneumonia, 2 with pertussis accompanying pneumonia, 2 with Salmonella enteritis, 1 with impetigo staphylogenes and 1 with subdural abscess, were adopted for the evaluation, and the other 4 were excluded from the evaluation because of inadequate indications. The efficacy rate in these 15 cases was 93.3%. The doses used in 14 out of the evaluated 15 cases ranged from 31 to 50 mg/kg/day, the frequency of dosing was twice daily in 8 cases and 3 times daily in 7 cases. One shot intravenous injection was used in 6 cases, intravenous drip infusion in 8, and combination of these, in 1 case. The duration of treatment was 2 days in 3 cases, 3 days in 3, 4 days in 4, and 5 days in 3 cases. Patients with severe infections were generally given large doses for long-term. No clinical adverse event was observed in any case. In laboratory examinations, slight elevation of S-GPT alone was observed in 1 case. From the above results, CAZ was considered to be a highly useful drug in the field of pediatrics.